Scinai Immunotherapeutics Ltd. American Depositary Shares (SCNI)

FairStock Score: 45/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At the 2026-10-13 close of $1.23, FairStock calculates a P/E of 0.04, a P/B of 0.71, a Graham Number of $33.15, and a margin of safety of 96.29%. That looks like a classic Graham bargain, but the filed record tells a different story. In fiscal 2021, the company reported a net loss of $8.2 million and diluted EPS of -$0.02; in fiscal 2022, a net loss of $5.8 million and diluted EPS of -$0.01; both years had no revenue in the filed figures. In fiscal Q1 2023, the net loss was $3.5 million. FairStock's health checks are ugly: Piotroski F-Score 1/9, Altman Z-Score -10.22, ROE -26.53%, ROCE -36.15%, and trailing free cash flow of -$6.6 million. With a market cap of only $1.9 million, the FCF yield of -353.4% means the company burns many times its market value. Debt/equity of 0.31 is modest, so leverage is not the immediate killer; cash burn is. The business has a focused pipeline in IL-17 NanoAb and PC111 and offers contract manufacturing, but the filed history shows only two years of results and no Lynch category. The FairStock Score of 45/100 and the lack of revenue in fiscal 2021 and 2022 leave little margin of safety in operating terms. Statistically cheap, financially fragile.

In plain English: Scinai is a tiny biotech that develops antibody treatments for inflammatory diseases and also offers contract manufacturing. The business looks weak: it has been losing money, burning cash, and has a short filed history. The share price looks cheap against its stated accounting value, but that cheapness reflects high risk rather than a strong, profitable business.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q1 2023 10-Q (period ended 2023-03-31) · fiscal Q1 2022 10-Q (period ended 2022-03-31) · FY2022 10-K (period ended 2022-12-31) · FY2021 10-K (period ended 2021-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer